Luke Timmerman is a trained journalist who has worked for quite some time in biotech journalism. He gives a brief history of his life and work history over the years, and his journey to becoming a biotech journalist. He went through some challenges especially writing for different contexts such as business audiences and insiders. He has strived to be a journalist known for the quality of his work rather than the number of clicks. There are tremendous possibilities in the biotech field, writing in this context is promising, Timmerman recounts when he started writing and how he felt privileged working especially with work on cancer. Public engagement is important but not always necessary. Money has a significant role in biotech, especially financing research and development (R&D); there is a need for the researchers to fund their projects and be assured that they can get something back from their exploration, but it should never hijack the motives to practice good science (Timmerman).
There are challenges, but FDA has been very supportive to researchers, which can be reflected by the number of new drug approvals. He offers interesting insights into cancer, the need for medical knowledge instead of general information, people have to rely on information that came from clinical trials and can be proved if there is a need. The field is highly dynamic, especially with the evolution of technology. He explores the potential of the biotech industry talking of some companies and the contribution to the entire body of biotech R&D. foundations such as the Gates Foundation have been supporting R&D; he suggests that we can be approaching a future where the clinical trials have shorter timelines, especially with the use of emerging technologies, such as precision medicine. The shorter timelines have high-cost cutting margins; precision medicine departs from the conventional premises of clinical trials and earning approvals from FDA. His experience in working as a biotech journalist has given him in-depth industry knowledge with several publications to his name (Timmerman).
Works Cited
Timmerman, Luke. "A Short History of Cures for Hepatitis C". Timmerman Report (2016): n. pag. Print.
Timmerman, Luke. "Big Pharma May Be a Dinosaur, But It Can Move Fast When It Wants".Timmerman Report (2016): n. pag. Print.
Timmerman, Luke. "Go-Go Years Have Been Good For Biotech, But Service Providers Are Feeling The Strain". Timmerman Report (2016): n. pag. Print.
Timmerman, Luke. "Illumina, Arch, Bezos, Gates Bet $100M on Deep Sequencing for Early Cancer Detection". Timmerman Report (2016): n. pag. Print.
Timmerman, Luke. "Post-JPM Perspective, FDA Shoots Down DMD Drug, & Illumina’S Audacity".Timmerman Report (2016): n. pag. Print.
